Larsen J P, Nessler E G, Hestnes A, Vilming S, Holmsen R, Aksnes V, Johnson S, Brodtkorb E, Hunstad N A, Helle J R
Nevrologisk avdeling, Sentralsjukehuset i Rogaland, Stavanger.
Tidsskr Nor Laegeforen. 1991 Oct 30;111(26):3163-6.
The majority of parkinsonian patients on long-term treatment with levodopa develop fluctuations in motor performance. Several of the features of long-term levodopa treatment seem to be associated with levodopa concentrations in the plasma. In order to overcome the dose-related clinical fluctuations, sustained or controlled-release oral tablets have been developed to achieve more stable plasma concentrations of the drug. This paper describes a Norwegian multi-centre study of Sinemet CR in 56 patients with mild to moderate parkinsonism. After 24 weeks on Sinemet CR the performance of 40 patients was evaluated as improved, i.e. better than when they were treated with standard levodopa. Patients with mild disease or with no motor fluctuations experienced similar clinical benefit from controlled-release levodopa as the more advanced parkinsonian patients. The authors also discuss the advantages and problems of controlled-release levodopa in parkinsonian patients in general.
大多数长期接受左旋多巴治疗的帕金森病患者会出现运动功能波动。长期左旋多巴治疗的一些特征似乎与血浆中左旋多巴浓度有关。为了克服与剂量相关的临床波动，已开发出缓释或控释口服片剂，以实现更稳定的药物血浆浓度。本文描述了一项在挪威对56例轻至中度帕金森病患者使用息宁控释片的多中心研究。使用息宁控释片24周后，40例患者的病情评估为有所改善，即比使用标准左旋多巴治疗时更好。轻症患者或无运动波动的患者从控释左旋多巴中获得的临床益处与病情更严重的帕金森病患者相似。作者还讨论了控释左旋多巴在帕金森病患者中的总体优势和问题。
